Login to Your Account



Clinic Roundup


Wednesday, July 24, 2013

• Prana Biotechnology Ltd., of Parkville, Australia, said it completed its Phase II Reach2HD trial testing PBT2 in patients with early to midstage Huntington's disease. Results from the 109-patient study are expected in October. The primary outcome is safety and tolerability, with secondary outcomes including measures from the cognitive, motor and behavioral domains affected in Huntington's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription